You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Neurocrin reported record net product sales exceeding $1.1 billion, up more than 40% year-over-year, and record operating profitability in third-quarter 2026. Ingressa sales were $801 million, and full-year guidance rose to $2.9 to $2.925 billion.
Neurocrine Biosciences’ first nine months of 2026 net product sales rose $848.7 million, or 41.7%, to $2.9 billion, driven by CRENESSITY and INGREZZA growth plus VYKAT XR sales following the May 18, 2026 Soleno acquisition.
Neurocrine Biosciences reported third-quarter 2026 revenue of $1.1 billion, up 41% year-over-year. It raised INGREZZA 2026 sales guidance to $2.9 to $2.925 billion and reported approximately $790 million in cash, cash equivalents and marketable securities.
Neurocrine Biosciences, Inc. appointed Eiry W. Roberts, M.D. as Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, M.D., whose service ended September 25, 2026; Dr. Keswani is entitled to severance benefits under the Executive Severance Plan.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP cost of revenues non-GAAP | 52.2M | Nine Months Ended September 30, 2026 | — |
| Non-GAAP net income non-GAAP | 843.9M | Nine Months Ended September 30, 2026 | — |
| Non-GAAP other income, net non-GAAP | 47.9M | Nine Months Ended September 30, 2026 | — |
| Non-GAAP R&D non-GAAP | 865.1M | Nine Months Ended September 30, 2026 | — |
| Non-GAAP SG&A non-GAAP | 912.7M | Nine Months Ended September 30, 2026 | — |
| reimbursement for dispensed prescriptions | 80% | third-quarter 2026 | — |
| Number of shares repurchased | 0.1M | the three months ended June 30, 2026 filing | — |
| Total cost of shares | $10M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NBIX
this stock
Neurocrine Biosciences Inc
|
$16.94B | +18.0% | +977.5% | 24.8 | 5.8% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.47B | +37.5% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$53.23B | +10.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$51.92B | +42.6% | +4.3% | 101.1 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Neurocrine Biosciences’ first nine months of 2026 net product sales rose $848.7 million, or 41.7%, to $2.9 billion, driven by CRENESSITY and INGREZZA growth plus VYKAT XR sales following the May 18, 2026 Soleno acquisition.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NBIX | +1.7% | +23.4% | +7.5% | +14.6% | +18.0% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -0.9% | +24.5% | +7.0% | +14.8% | +7.4% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
